| Literature DB >> 32896189 |
Bobin Mi1, Lang Chen1, Dake Tong2, Adriana C Panayi3, Fang Ji4, Junfei Guo5, Zhiyong Ou5, Yingze Zhang5, Yuan Xiong1, Guohui Liu1.
Abstract
Background and purpose - Following the outbreak of COVID-19 in December 2019, in China, many hip fracture patients were unable to gain timely admission and surgery. We assessed whether delayed surgery improves hip joint function and reduces major complications better than nonoperative therapy. Patients and methods - In this retrospective observational study, we collected data from 24 different hospitals from January 1, 2020, to July 20, 2020. 145 patients with hip fractures aged 65 years or older were eligible. Clinical data was extracted from electronic medical records. The primary outcomes were visual analogue scale (VAS) score and Harris Hip Score. Major complications, including deep venous thrombosis (DVT) and pneumonia within 1 month and 3 months, were collected for further analysis. Results - Of the 145 hip fracture patients 108 (median age 72; 70 females) received delayed surgery and 37 (median age 74; 20 females) received nonoperative therapy. The median time from hip fracture injury to surgery was 33 days (IQR 24-48) in the delayed surgery group. Hypertension, in about half of the patients in both groups, and cerebral infarction, in around a quarter of patients in both groups, were the most common comorbidities. Both VAS score and Harris Hip Score were superior in the delayed surgery group. At the 3-month follow-up, the median VAS score was 1 in the delayed surgery group and 2.5 in the nonoperative group (p < 0.001). Also, the percentage of complications was higher in the nonoperative group (p = 0.004 for DVT, p < 0.001 for pulmonary infection). Interpretation - In hip fracture patients, delayed surgery compared with nonoperative therapy significantly improved hip function and reduced various major complications.Entities:
Mesh:
Year: 2020 PMID: 32896189 PMCID: PMC8023940 DOI: 10.1080/17453674.2020.1816617
Source DB: PubMed Journal: Acta Orthop ISSN: 1745-3674 Impact factor: 3.717
Figure 1.Flow chart of study design.
Demographics, clinical characteristics, and treatment of elderly hip fracture patients during the COVID-19 pandemic
| All | Surgery | Nonoperative | ||
|---|---|---|---|---|
| Factor | n = 145 | n = 108 | n = 37 | p-value |
| Demographics | ||||
| Female sex | 90 | 70 | 20 | 0.2 |
| Age, mean | 72 | 72 | 74 | 0.2 |
| range | 66–81 | 65–79 | 66–85 | |
| Chronic comorbidity | ||||
| Hypertension | 81 | 62 | 19 | 0.5 |
| Diabetes | 29 | 18 | 11 | 0.09 |
| Cerebral infarction | 40 | 29 | 11 | 0.7 |
| Coronary heart disease | 23 | 15 | 8 | 0.3 |
| Osteoporosis | 10 | 9 | 1 | 0.4 |
| Prior medical history | ||||
| Smoking | 20 | 15 | 5 | 1.0 |
| Alcohol | 16 | 12 | 4 | 1.0 |
| Other clinical characteristics | ||||
| Simple fall | 118 | 88 | 30 | 1.0 |
| Traffic accident | 15 | 11 | 4 | 1.0 |
| Fall from height | 6 | 4 | 2 | 1.0 |
| Sprain | 6 | 5 | 1 | 1.0 |
| Femoral fracture type | ||||
| Neck | 105 | 88 | 17 | < 0.001 |
| Intertrochanteric | 36 | 17 | 19 | < 0.001 |
| Subtrochanteric | 4 | 3 | 1 | 1.0 |
| Brain injury | 5 | 4 | 1 | 1.0 |
| Treatment | ||||
| Traction | 41 | 32 | 9 | 0.5 |
| Analgesics | 116 | 86 | 30 | 0.8 |
| Antibiotics | 68 | 56 | 12 | 0.04 |
Intraoperative data of 108 surgical patients
| All | Plate | Dynamic | Proximal | Hip | Hollow | |
|---|---|---|---|---|---|---|
| n = 108 | n = 12 | n = 6 | n = 15 | n = 68 | n = 7 | |
| Femoral fracture typ, n | ||||||
| neck | 88 | 7 | 5 | 2 | 67 | 7 |
| intertrochanteric | 17 | 5 | 0 | 11 | 1 | 0 |
| subtrochanteric | 3 | 0 | 1 | 2 | 0 | 0 |
| Days from injury to surgery | 33 | 32 | 45 | 29 | 37 | 23 |
| IQR | 24–48 | 25–58 | 26–71 | 22–44 | 25–49 | 21–38 |
| Surgery time, minutes | 90 | 133 | 95 | 90 | 80 | 90 |
| IQR | 60–120 | 60–173 | 80–110 | 60–135 | 60–120 | 40–120 |
| Intraoperative blood loss, mL | 200 | 150 | 225 | 200 | 200 | 50 |
| IQR | 100–300 | 100–400 | 118–425 | 100–400 | 120–300 | 30–100 |
1-month follow-up results of 145 elderly hip fracture patients during the pandemic of COVID-19
| All | Surgery | Nonoperative | ||
|---|---|---|---|---|
| Items | n = 145 | n = 108 | n = 37 | p-value |
| Deep venous thrombosis, n | 20 | 11 | 9 | 0.03 |
| Pulmonary infection, n | 24 | 14 | 10 | 0.03 |
| VAS score (0–10) | 3.0 | 3.0 | 5.0 | < 0.001 |
| IQR | 2.0–4.0 | 1.3–4.0 | 3.0–6.5 | |
| Harris Hip Score (0–100) | 69 | 71 | 66 | 0.04 |
| IQR | 57–82 | 60–84 | 55–82 |
3-month follow-up results of 133 elderly hip fracture patients during the COVID-19 pandemic
| All | Surgery | Nonoperative | ||
|---|---|---|---|---|
| Items | n = 133 | n = 99 | n = 34 | p-value a |
| Deep venous thrombosis, n | 25 | 13 | 12 | 0.004 |
| Pulmonary infection, n | 31 | 15 | 16 | < 0.001 |
| VAS score (0–10) | 1.0 | 1.0 | 2.5 | < 0.001 |
| IQR | 0.0–3.0 | 0.0–2.0 | 1.0–5.0 | |
| Harris Hip Score (0–100) | 71 | 73 | 70 | 0.04 |
| IQR | 63–85 | 66–86 | 58–84 | |
| Dead | 5 | 1 | 4 | 0.02 |
Mann–Whitney U-test or chi-square test was selected to compare differences between surgery and conservative therapy where appropriate.
Demographics, clinical characteristics, and causes of death of 6 dead elderly hip fracture patients during the COVID-19 pandemic
| Patient | Therapy | Sex | Age | Hyper- | Dia- | Cerebral | Other chronic comorbidity | Cause of death | Days from |
|---|---|---|---|---|---|---|---|---|---|
| 1 | surgical | female | 84 | + | + | + | Chronic obstructive pulmonary disease | Pulmonary infection | 78 |
| 2 | nonoperative | male | 80 | – | – | + | Pleural effusion, arrhythmia, atrial fibrillation | Heart failure | 18 |
| 3 | nonoperative | male | 87 | – | – | – | Pulmonary infection, pulmonary tuberculosis, | Pulmonary embolism | 27 |
| 4 | nonoperative | female | 71 | + | – | + | Coronary heart disease, arrhythmia | Heart failure | 69 |
| 5 | nonoperative | male | 73 | + | + | + | Coronary heart disease | Heart failure | 88 |
| 6 | nonoperative | male | 85 | + | + | – | Renal failure | Renal failure | 169 |
Figure 2.Kaplan–Meier curves of survival. Gehan–Breslow–Wilcoxon test p-value = 0.003; hazard ratio, surgery versus nonoperative therapy group = 0.06 (95% confidence interval 0.01–0.38).